Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
42.56
-1.09 (-2.50%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.

It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.

The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.

Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.

The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.
Avidity Biosciences logo
Country United States
Founded 2012
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 253
CEO Sarah Boyce

Contact Details

Address:
10578 Science Center Drive, Suite 125
San Diego, California 92121
United States
Phone 858 401 7900
Website aviditybiosciences.com

Stock Details

Ticker Symbol RNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001574111
CUSIP Number 05370A108
ISIN Number US05370A1088
SIC Code 2834

Key Executives

Name Position
Sarah Boyce President, Chief Executive Officer and Director
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder and Independent Chairman
Dr. W. Michael F. Flanagan Ph.D. Chief Scientific and Technical Officer
Teresa McCarthy Chief Human Resources Officer
Dr. Arthur A. Levin Ph.D. Distinguished Scientist, Strategic Leader and Director
Eric B. Mosbrooker Chief Strategy Officer
Prof. Mark E. Davis Ph.D. Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Dr. Frank P. McCormick Ph.D. Scientific Founder and Member of Scientific Advisory Board
John B. Moriarty Jr., ESQ., J.D. Chief Legal Officer and Corporate Secretary
Dr. John W. Wallen III, J.D., Ph.D. Consultant

Latest SEC Filings

Date Type Title
Feb 16, 2016 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2016 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 8, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 30, 2015 20-F Annual and transition report of foreign private issuers
Mar 23, 2015 15-12B Securities registration termination
Feb 17, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2015 6-K Report of foreign issuer
Feb 12, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 11, 2015 25 Filing
Feb 10, 2015 6-K Report of foreign issuer